Kura Oncology Reports First Quarter 2023 Financial Results
May 10, 2023 16:03 ET
|
Kura Oncology, Inc.
– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML...
Quantexa Provides ING with Solution to Strengthen and Automate Global Risk Coverage
May 10, 2023 08:00 ET
|
Quantexa
LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Today Quantexa, a global leader in Decision Intelligence (DI) solutions for the public and private sectors, announced that ING is deploying Quantexa’s...
Kura Oncology to Participate in JMP Securities Life Sciences Conference
May 09, 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Oncotelic Launches PDAO SEC Chatbot
April 24, 2023 07:30 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), , today announced the beta launch of a proprietary...
Melissa Advises Negative News Screening for Onboarding Business Customers
April 05, 2023 08:00 ET
|
Melissa
RANCHO SANTA MARGARITA, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Melissa, a leading provider of global data quality, identity verification, and address management solutions, today advised...
AB Science annonce une première réponse complète de la moelle osseuse chez un patient atteint de leucémie myéloïde aigue réfractaire en rechute, à très faible dose, dans son essai clinique de phase I/II avec AB8939 (AB18001)
March 13, 2023 13:10 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE UNE PREMIÈRE RÉPONSE COMPLÈTE DE LA MOELLE OSSEUSE CHEZ UN PATIENT ATTEINT DE LEUCÉMIE MYÉLOÏDE AIGUË (LMA) RÉFRACTAIRE EN RECHUTE, A TRÈS FAIBLE DOSE, DANS...
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)
March 13, 2023 13:10 ET
|
AB Science
PRESS RELEASE AB SCIENCE REPORTS A FIRST COMPLETE BONE MARROW RESPONSE IN A RELAPSED REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENT FROM THE VERY LOW DOSE ARM OF ITS AB8939 PHASE I/II CLINICAL TRIAL...
Cytek® Biosciences Introduces New 20-Color AML Panel
March 07, 2023 17:00 ET
|
Cytek Biosciences, Inc.
FREMONT, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the launch of a new 20-Color Acute Myeloid...
CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
March 07, 2023 12:49 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read...
Precipio continues to sign up and onboard HemeScreen™ customers
March 07, 2023 12:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) continues to convert its sales pipeline into HemeScreen customers, with an...